Summarized by Masters of Longevity from Neuroscience News.
A news article about preclinical research on a natural peptide that targets multiple pathological features of neurodegeneration, inviting readers curious about a multi‑modal therapeutic approach.
Key Takeaways
- Catestatin, a chromogranin A–derived peptide, reduced both amyloid and tau aggregates in mouse models of neurodegeneration.
- Treatment with catestatin decreased markers of neuroinflammation and improved cognitive and motor performance in treated mice.
- Authors report the peptide may reprogram brain energy metabolism, but findings remain preclinical and require human safety studies.
